A positive development from the health sector come to the fore as state-run National Institute of Health (NIH) has produced the first batch of single-dose PakVac, a made-in-Pakistan vaccine.
The Chinese vaccine has been renamed PakVac and by the end of the month, its first batch will be available for administration.
Taking to his Twitter handle, Dr Faisal Sultan, Special Assistant to Prime Minister Imran Khan on Health, congratulated the NIH team for its rigorous efforts.
Congratulations to the NIH Pak team and its leadership for successful fill/finish (from concentrate) of the Cansino vaccine with the help of Cansino Bio Inc. China. The product has passed the rigorous internal QA testing. An imp step to help in our vaccine supply line pic.twitter.com/hrkySTJxPX
— Faisal Sultan (@fslsltn) May 24, 2021
The vaccine has cleared all internal quality control checks and testing at NIH’s quality control division and the results show that it is safe and effective for administration.
Read Also
Covid Hospitals in Karachi Fill to The Brim
So far, more than 100,000 CanSino jabs are being prepared by NIH.
With current capacity, NIH officials told they will be able to produce only 3 million doses per month after approval of Drug Regulatory Authority of Pakistan (DRAP).
NIH has prepared a sample dose to present before DRAP for a permit which is expected to be submitted within 48 hours and once approved, the vaccine can be used across the country.
Under the supervision of Chinese experts, PakVac has been successfully manufactured locally whereas all required raw materials were imported to Islamabad last month.